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This paper presents a programmatic perspective on the relationship 
between the introduction of new contraceptive technology and expanding 
contraceptive options, using the example of Cyclofem in Indonesia. 
Past approaches to contraceptive introduction have considered 
only the characteristics of the new method in the decision-making 
process. In assessing whether the introduction of a new method 
actually expands contraceptive choice for women and whether the 
program has the managerial capabilities to assure quality of care 
in this process, the authors argue that consideration must be given 
to all methods within a delivery system and how new technology relates 
to the management of contraceptive choice. Using this perspective, 
the authors suggest that choice would not necessarily be expanded 
with scaled-up service delivery of a new once-a month injectable 
in the Indonesian public sector context. 
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Introduction 
A central rationale behind contraceptive development and introduction 
is choice: Presenting potential users with a range of options so that they 
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can select a method best suited to their needs. However, whether or not 
users’ options are actually broadened when new contraceptive technology 
is added to a service delivery system has not been widely examined. 
The assumption has been that addition of new technology by definition 
increases choice. Past approaches have defined the central issues of contra- 
ceptive introduction in terms of safety, user acceptability and continua- 
tion rates of a new method of contraception. Using the example of 
Cyclofem introduction in Indonesia, we argue that a shift is needed away 
from an exclusive focus on the new method to an evaluation of new 
technology as it interacts with the existing service delivery system and 
with user needs. Within this approach the guiding research questions are 
as follows: Does the introduction of a new method expand contraceptive 
options for the user and does the program have the managerial capabilities 
to assure quality of care in the process of adding new contraceptive tech- 
nology to the existing method mix? This paper shows that an emphasis 
on programmatic factors rather than on the intrinsic characteristics of 
the method alone, dramatically alters conclusions about the impact of 
contraceptive introduction on choice. 
With the growing emphasis on quality of care in family planning,lj2 the 
importance of assuring meaningful and safe contraceptive options has 
become a central theme in both the professional literature and the policy 
and program arenas. Meaningful choice implies variability in the intrinsic 
characteristics of methods, including such features as mode of administra- 
tion, side-effects, duration and reversibility. New technology alone, how- 
ever, does not broaden choice. The degree to which options are actually 
expanded depends on the existing method mix in a given setting, and on 
the program’s capabilities to assure quality of care as new methods are 
added to the service delivery system. The most dramatic example of how 
the introduction of new technology by itself does not necessarily broaden 
choice is the history of intrauterine device (IUD) introduction in the 
196Os, when the Lippes loop was hailed as the breakthrough in contracep- 
tive technology that would solve India’s population problem. Because of 
its easy reversibility, the IUD signified a major expansion of options, at 
a time when hormonal methods were not yet available in India, and 
the only medical method available was sterilization. Given the lack of 
attention to the social and cultural implications of the IUD for traditional 
women, and the failure to adapt the service delivery system to assure 
appropriate standards of technical care, medical backup and counseling, 
the IUD soon became discredited among Indian women as an acceptable 
contraceptive method. 
In connection with the more recent introduction of Norplant and 
Cyclofem, so-called “introductory trials” have been organized upon com- 
pletion of phase III clinical trials with the intention of assuring appropriate 
preparation of the service delivery system for the requirements of the 
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new method. Closely modeled after the clinical trial in their research 
protocol, such introductory evaluations are intended to assess the safety, 
efficacy, acceptability and continuation rates of new technology under 
conditions that approximate routine service delivery, yet still benefit from 
special conditions. Given the additional inputs in supplies, staffing and 
training, and the relatively strong technical and managerial capabilities 
which are part of the selection criteria for introductory trial clinics, the 
addition of new technology is likely to broaden contraceptive options in 
these settings. Whether options are actually expanded, however, is usually 
not assessed. Introductory trial protocols are centered on outcome meas- 
ures pertaining to a single method and not on the relationship of this 
method to existing contraceptive methods and the broader service delivery 
system. Moreover, since they do not represent typical service delivery 
settings, introductory trials shed little light on the impact of new contra- 
ceptive technology on choice within routine service delivery systems. 
Assessment of such impact requires research with a programmatic focus, 
placing new technology into the context of the existing method mix and 
the management capabilities of average service delivery settings. This 
paper presents findings from the Indonesian Health Services Delivery 
Study on Cyclofem3, which adopted such a programmatic focus. We exam- 
ine the relationship between the introduction of the once-a-month in- 
jectable and choice, showing that contraceptive options for Indonesian 
women would not necessarily expand with scaled-up service delivery of 
Cyclofem. A companion paper in this volume by Lubis and colleagues 
presents key findings on the technical quality of care and on the necessary 
adaptations in program management to ensure maintenance of appropriate 
technical standards of service.4 
The Indonesian Health Services Delivery Study: Background, 
Framework and Methods 
The Indonesian Health Services Delivery Study examined the implica- 
tions of adding Cyclofem to the national family planning program while 
focusing on both quality of care and quality in management of the delivery 
system. At the time of the study’s initiation, an introductory trial of 
Cyclofem was underway in six public sector health centers in Indonesia. 
The first objective of the study was to assess the managerial and quality 
of care implications of adding Cyclofem to these health centers. A second 
objective of the study was to assess the managerial requirements and/or 
adaptations that would be necessary for the introduction of Cyclofem on 
a nationwide basis. Studying non-trial settings provided an opportunity 
to predict the effect of Cyclofem introduction on both quality of care and 
on quality of management within these delivery contexts. Examination 
of whether other forms of contraception, particularly other injectables, 
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were provided within a context of choice made it possible to anticipate 
the conditions of service delivery likely to characterize Cyclofem intro- 
duction within these same settings. The focus on quality of care and its 
managerial determinants is based on the argument that quality programs 
are likely to achieve high levels of adoption, use continuation and user 
satisfaction.” For the purposes of this study, quality of care was defined 
as judgments about appropriate service delivery related to three critical 
areas: choice, interpersonal quality of care and technical quality of care. 
The present paper focuses on choice, raising the following questions: I ) 
Does Cyclofem introduction actually broaden contraceptive options for 
women, and 2) What are the managerial requirements of assuring such 
choice? 
Assessing the managerial prerequisites of quality of care in the intro- 
duction of Cyclofem implies a need to develop contextual understandings 
and explanations of the service delivery system to which this new contra- 
ceptive will be added. Given the focus on management processes and 
implementation systems, a qualitative approach to data collection was 
chosen and combined with secondary quantitative data, to the extent 
that such data were available. Data collection consisted of systematic 
observation of service delivery, in-depth interviews and document re- 
views, and was conducted in the provinces where the introductory evalua- 
tions of Cyclofem were being conducted (Jakarta and West Java], as well 
as in West Sumatra, where the introductory trial was soon to be initiated 
as well. Observations were conducted in 28 service delivery sites, includ- 
ing: four of the six health centers involved in the introductory evaluation, 
seven non-trial health centers, four community-based health posts, and 
thirteen private sector settings. Non-trial health centers were selected 
purposely in each of the three provinces, in order to represent both urban 
and rural facilities, moderate resources and both average as well as weak 
program performance. Private sector settings consisted of physician or 
midwife practices or clinics of non-governmental organizations (NGOS). 
All methods provided in a given setting during the observation period were 
included in this study. A key characteristic of the observation technique in 
this study was to place the individual provider-client interactions into the 
context of the clinic session as a whole. The study instrument emphasized 
observation of patient flow through the clinic from the time a client 
approached the service delivery point to her exit from it. With this ap- 
proach, 241 individual provider-client interactions were observed (Ta- 
ble 1). In addition to clinic observations, a total of 107 in-depth interviews 
(Table 2) were conducted with: 
1. National leaders: in the National Family Planning Board (BKKBN,) in 
the Ministry of Health (MOH), from the Indonesian Medical Associa- 
tion, the Indonesian Midwives’ Association, the Association of Obste- 
512 Contraception 1994:49, May 
Role of Cyclofem in Indonesia: Simmons et al. 













7 18 9 17 2 53 
19 51 9 3 2 84 
na 22 16 8 1 47 
na 13 8 7 4 32 
na 7 11 3 2 23 
na 0 1 1 0 2 
TOTAL 26 111 54 39 11 241 
*Other contraceptive methods used include: condoms, vaginal tablet, tubectomy, and vasectomy. na = not 
applicable 
tricians and Gynecologists, the Indonesian Planned Parenthood 
Association, the Blue Circle Program; 
2. BKKBN and Ministry of Health leaders and program managers at the 
provincial and district level; 
3. Public and private sector providers of services in introductory as well 
as non-trial sites, in urban, semi-urban and rural areas including 
BKKBN and MOH fieldstaff, and with providers at selected health 
centers, as well as with officials and reproductive health leaders at the 
provincial and national levels; 
4. Community leaders as represented by village leaders, their wives and 
formal village women’s groups; 
5. Clients, including both Cyclofem acceptors and dropouts in trial areas, 
and users of other injectables and other methods in non-trial areas. 
Choice in Trial Centers and Future Potential for Choice in the 
Public Sector 
Cyclofem Introduction in Trial Centers Increased Options for Some 
Women 
Information about the availability of contraceptive methods both at the 
community level and at health centers and health posts has been widely 
disseminated in Indonesia throughout the past several years. Family plan- 
ning fieldworkers, their supervisors, village cadres, village leaders and a 
range of other community groups and institutions have been utilized 
to spread information about and mobilize demand for family planning 
Contraception 1994:49, May 513 
Role of Cyclofem in Indonesia: Simmons et al. 
TABLE 2. Number of interviews conducted 
I. Number of Providers and Clients Interviewed by Province 
PROVIDERS CLIENTS 
DMPAI 
Community FP Cyclofem Cyclofem NET-EN 
Doctor Midwife Leaders Fieldstaff Users Drop-outs Users TOTAL 
Jakarta 
Trial health centers 1 2 2 2 5 
Non-trial health 
centers 1 2 - na 
Private sector 2 1 na na na 
West Java 
Trial health centers 5 3 1 1 5 
Non-trial health 
centers 1 1 3 3 na 
Private sector 3 2 na na na 
West Sumatra* 
Trial health centers 2 3 na 
Non-trial health 
centers 2 4 3 2 na 
Private sector 3 2 na na na 
Total 20 20 9 8 10 
II. Number of Program Officials and Professional Leaders Interviewed 
Ministry Professional 








na 2 13 
na - 5 









National level 9 3 4 16 
Provincial level 5 4 9 
Total 14 7 4 25 
GRAND TOTAL INTERVIEWED 107 
*These interviews were conducted in anticipation of inclusion of West Sumatra health centers in phase II of 
the Cyclofem introductory trial. na = not applicable. 
services.h,7 The Cyclofem introductory trial protocol, however, did not 
permit such promotional activities, thus information about this method 
within communities was limited. 
In the Indonesian Family Planning Program, women identified as candi- 
dates for long term methods tend to be encouraged to use the IUD, occa- 
sionally sterilization, and more recently Nor-plant, while women wishing 
to space births are directed towards the pill and injectables. Cyclofem was 
typically introduced within the context of other injectable contraceptive 
service delivery. Women who came to the health center wanting an in- 
jectable or who were already using one were offered the once-a-month 
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injectable, particularly if they complained about amenorrhea or irregular 
bleeding, side-effects which are less common with Cyclofem.x Introduc- 
tory trial statistics confirmed that Cyclofem is predominantly provided 
to the subgroup of women who were either using an injectable or inter- 
ested in using one. Forty-seven percent of Cyclofem users had switched 
from depot-medroxyprogesterone acetate (DMPA) use, 4 percent from 
norethisterone enantate (NET-EN) and Cyclofem, while 13 percent adop- 
tion was from pill users, 4 percent from the IUD, 4 percent from among 
other methods, and 29 percent from “new” contraceptive acceptors.y In the 
introductoryide trial, new acceptors were defined as women not currently 
using a contraceptive. This includes both women who may have used 
one previously, including an injectable, and discontinued, and those who 
have never used a family planning method. 
The introductory study of Cyclofem has expanded women’s options 
in two respects. First, the intrinsic characteristics of the once-a-month 
injectable (regular bleeding patterns and quick return of fertility) provided 
additional variability to the existing contraceptive mix. Some women 
were given the opportunity to take advantage of this new option. Second, 
choice was expanded because women received a degree of information 
about the method not typically available in the Indonesian national pro- 
gram: written materials and information concerning benefits and pattern 
of follow-up. Possible side-effects, however, were not regularly mentioned. 
New acceptors of other methods receive only a limited amount of informa- 
tion from the health center staff. From a technical point of view, the 
quality of service delivery of Cyclofem also distinguished itself from other 
methods, as is discussed by Lubis et a1.4 
Nonetheless, expansion of choice in introductory trial settings was 
relatively modest. Within the public sector program, the availability of 
two other injectables placed clear limits on Cyclofem’s contribution to 
the intrinsic variability of the contraceptive mix. The earlier addition of 
Norplant to the Indonesian program, by contrast, amounted to a signifi- 
cant expansion of method mix characteristics. In a Muslim society where 
sterilization or the pelvic examinations associated with IUD insertion 
have limited social and cultural acceptability, an additional long-acting 
method avoiding these social taboos has the potential of making a substan- 
tial contribution. Given the apparent rapid return to fertility, its easy 
reversibility, regular bleeding patterns, and high efficacy, Cyclofem has 
distinct advantages for young women, who would have reason for concern 
with the delay in return to fertility that usually characterizes DMPA. 
The advantages of the method for young women who wish to delay the 
onset of childbearing or to space the timing of childbirth were not given 
emphasis, however. Interest in the needs of the very young women at the 
beginning of their reproductive period is only now emerging as a policy 
emphasis of the Indonesian family planning program (Dr. Pandi, personal 
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communication). At the time the fieldwork for this study was conducted, 
however, this interest had not yet been translated into patterns of service 
delivery at local health centers and trial health centers did not draw 
attention to Cyclofem’s special relevance for young women. 
The value of Cyclofem’s more regular bleeding patterns was somewhat 
diminished by the availability of alternative options for addressing the 
frequent side-effects associated with DMPA use. Interviews with both 
providers and women established that DMPA users complaining about 
amenorrhea did not necessarily desire a regular monthly bleeding pattern, 
but were quite satisfied with an occasional period. Some providers broke 
the pattern of amenorrhea by stopping the injectable and providing one 
or two cycles of oral contraceptives, even though the possibility of incon- 
sistent use of the pill exposed women to increased risk of pregnancy. A 
number of providers reported that with appropriate counseling at the time 
of the initial injection, side-effects of DMPA, especially amenorrhea, were 
frequently well tolerated. Such counseling, however, was not practiced 
regularly in the public sector program, as has also been noted in the 
literature.“,‘,‘” 
Of additional relevance to choice is the cost of contraception. In the 
introductory study, Cyclofem was provided without fee while other in- 
jectables were subject to varying degrees of locally levied charges, or had 
to be purchased through a private pharmacy, in an attempt to shift services 
towards self-sustainability. Future use of Cyclofem within the national 
program would involve similar charges. With the more frequent returns 
to the health center for services, user costs for Cyclofem in terms of 
transportation, time loss and other opportunity costs would be higher 
than those for the other injectables. 
The Availability of NET-EN and DMPA in Routine Service Delivery 
has not Expanded Choice 
Two injectables are currently available in the Indonesian National Family 
Planning Program: DMPA and NET-EN. Both of these are progestogen- 
only contraceptives, which are often associated with disruption of normal 
menstrual bleeding, resulting in either amenorrhea or spotting.x,‘l DMPA 
is administered every three months and NET-EN initially every two 
months and after the third injection, every three months. Injectable con- 
traceptives were introduced into the government program in the late 
I970s, having been available several years earlier in the private sector 
and through special projects. At the time of this study, DMPA was the 
most widely used injectable. The general consensus among managers and 
providers was that injectables are a highly favored method of contracep- 
tion because injections are generally well liked and associated with effec- 
tive medical care. According to the 1991 Indonesian Demographic and 
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Health survey, 11.7 percent of currently married women were using 
DMPA or NET-EN, making injectables the third most popular contracep- 
tive method in Indonesia after the pill and the IUD (14.8 and 13.4 percent, 
respectively). 
Even though NET-EN and DMPA are very similar to each other, the 
two injectables are distinct in their pattern of side-effects.8 Discontinua- 
tion rates due to irregular bleeding are the same for both injectables, while 
discontinuation rates for amenorrhea are lower for NET-EN.” Examining 
how the availability of two injectables in the current program has affected 
women’s choices, provides insight into the likely conditions of Cyclofem 
service delivery, if the method were introduced on a large scale. It was 
consistently observed that the differences between these two injectables 
were not emphasized to prospective clients. The practice was to substitute 
NET-EN for DMPA when stock depletion or logistics bottlenecks led to 
unavailability of DMPA. Typically, patients were not informed of the 
substitution. When women noticed the difference, providers reassuringly 
proclaimed there was none, except that an initial return visit was required 
in two instead of three months. Providers dislike NET-EN because it is 
an oil-based solution and, therefore, more difficult to inject. Since 
the program did not provide the appropriate bore needles for NET-EN, the 
injection was made unnecessarily cumbersome for the provider, given the 
difficulty of injecting the more viscous solution through a smaller bore 
needle. Under these conditions, injection of NET-EN is also more painful 
for the user. NET-EN and DMPA were supplied to public sector providers 
without regard to local demand or peripheral supplies such as needles. 
Although the preferred injectable was DMPA, intermittently health cen- 
ters received, stocked and supplied only NET-EN. Thus, the existence of 
two progestogen-based injectables had not increased choice and, in fact, 
had reduced it in those cases in which women do not receive their pre- 
ferred injectable because another has been substituted. 
The pattern observed for NET-EN and DMPA was similar for IUDs as 
well. Of the three different IUDs available in the public sector program, 
at least two, the Multiload and the Lippes loop, were typically in stock 
at the health center. The Copper T was less frequently available. In discus- 
sions with the client, and subsequent decision-making about IUD adop- 
tion, the differences among IUDs were rarely identified. Providers did not 
consider systematically which type of IUD would be most appropriate 
for each individual woman. For example, we observed a midwife who 
after insertion of the Multiload IUD realized that the woman had pre- 
viously used an IUD for eight years and did not want any more children. 
The midwife commented to the observer: “Oh, I should have inserted a 
Lippes loop IUD, so she doesn’t have to change it after four years.” 
Cyclofem, on the other hand, was generally distinguished from the 
other injectables both in the minds of the provider and the client. Its 
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introduction had, therefore, expanded injectable choice in introductory 
study centers. Choice was also expanded in that Cyclofem’s intrinsic 
characteristics are notably different from those of the progestogen-based 
injectables, although as mentioned above, the additional contribution to 
the expansion of the method mix was modest. Unless the service delivery 
system informs users of the differences among methods, and of each 
method’s relative advantages and disadvantages, and assures consistent 
and affordable supplies of each injectable, choice will remain constrained. 
Findings on service provision of DMPA and NET-EN under conditions of 
routine service delivery do not bode well for the integration of an addi- 
tional injectable, unless a major effort is to be made to differentiate the 
new technology from the other methods through counseling, information- 
giving and better management of logistics and supplies. 
Policy and Managerial Constraints Impeding Expansion of 
Choice in the Public Sector 
Several managerial and policy barriers restrict choice in the Indonesian 
program and are likely to hamper effective service expansion of Cyclofem 
as well. 
Emphasis on Long-acting Methods 
During recent years, the Indonesian Family Planning Program has moved 
toward greater emphasis on long-term contraceptive methods, including 
the IUD, Norplant and sterilization. ln,12 This policy translates into specific 
targets at all program levels, profoundly affecting service delivery.’ Accep- 
tance of long-acting methods, and especially of the IUD, was highly valued 
by health center providers, subverting in several instances the objectives 
of the Cyclofem introductory study, and those relating to choice more 
generally. For example, we observed a woman who went to the midwife 
asking for family planning. The midwife asked: “Do you want the IUD or 
the implant?” The woman answered: “No, I don’t, I want the injectable”. 
Whereupon the midwife commented to the observer: “It is difficult. If 
the patient already wants the injectable, it is difficult to change her mind”. 
Emphasis on long-acting methods was observed consistently in the 
public sector both in trial and non-trial health centers. With this overrid- 
ing concern, Cyclofem was not mentioned to women who came to the 
health center asking for the IUD, while requests for injectables were 
countered with the suggestion to use a long-term method. This tendency 
has also been noted in Pariani’s study of contraceptive choice in East 
Java.ls Such emphasis on long-acting methods did not translate into refusal 
to accommodate women’s initial requests, however. Women tended to 
leave the health center with the method to which they had declared an 
interest upon arrival. 
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De-emphasis on Injectables in the Public Sector through Curtailed 
Supplies and Cost Recovery Efforts 
Injectables within the public sector were furthermore de-emphasized 
through cost recovery and limited supplies. The intention was to shift 
the financial burden of injectables increasingly to the private sector or to 
seek cost recovery within the public sector health center. Clients were 
charged variable rates for injectables (with the exception of Cyclofem), 
while other contraceptives were provided free of charge. Also, mentioned 
by providers in several instances, was the National Family Planning 
Board’s practice of supplying less than the needed number of injectables 
to health centers. 
Lack of Differentiation between Injectables in Record Keeping and 
Logistics Systems 
Certain features of the record keeping system impede available injectable 
options. Both DMPA and NET-EN are recorded under the category “sunti- 
kan”, which translates into “injectable”. Thus, the record keeping system 
cannot provide information on the number of users of each injectable, 
nor can the logistics system adjust the supply to clinic-based information 
on levels of demand. The administrative burden of adjusting a large, 
complex national program to the requirements of new contraceptive mo- 
dalities, as well as inadequate awareness of the quality of care implications 
of such failure, are likely explanations for this lack of differentiation. 
Inadequate Emphasis on Information Giving and Counseling 
The concept and philosophy of counseling are now receiving somewhat 
greater attention in the Indonesian program than in the past. However, 
in terms of general program implementation, there is currently no culture 
which asks questions, or emphasizes the importance of listening to wom- 
en’s needs and expression of feelings, or encourages women to make their 
own decisions.6,7,10J4 The expectation that exchanges between providers 
and clients are to be brief is so well understood that women refrain from 
raising their concerns, knowing that providers answer questions in only 
the most perfunctory manner. 
Information concerning the range of family planning options available 
and their respective advantages and disadvantages was not emphasized 
in service delivery. Program representatives often claimed that this func- 
tion is performed through community-based program agents, while 
women typically reported that decisions were made based on the experi- 
ence of friends and neighbors. Without attention to the information-giving 
component of care in clinic services, the meaningfulness of available 
contraceptive options is severely undermined. 
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Burden on Staff Time 
Availability and utilization of staff time constitute an additional impedi- 
ment to the expansion of choice in the event of nationwide introduction 
of Cyclofem. Health center staff spent limited amounts of time with each 
client to assure speedy services to all patients, and in order to complete 
clinic sessions within the morning hours, typically considered available 
for clinic services. Introduction of Cyclofem would increase monthly 
patient loads in comparison with the amount of time required for reinjec- 
tion of patients using a three-monthly injectable. Such increased pressure 
for service delivery does not enhance informed choice. 
Potential for Cyclofem in the Private Sector 
How appropriate are once-a-month injectables for the private sector? In 
Indonesia, the private sector is more varied than the public sector, con- 
sisting of practices of obstetricians and gynecologists, midwives, general- 
ist private practitioners, and clinics organized by non-governmental 
organizations. Findings consistently indicate a considerable degree of 
choice and information-giving in the private sector. In contrast to the 
public sector, where women generally expressed a firm contraceptive 
preference, women using the private sector often had not made up their 
minds about which contraceptive to use. They tended more often to ask 
the provider for advice, or even to make the decision on their behalf. 
Private providers did not hesitate to offer their own opinion, but unlike 
the pattern in the public sector, such advocacy was based on patient 
needs, rather than on policy directives. Doctors and NGOs were observed 
to present fairly balanced and accurate technical information. Midwives 
in rural areas, however, conducted extensive conversations with women, 
with a focus on building trust and showing empathy, but transferal of 
correct factual information was limited. 
NGO clinics offered a full range of contraceptive options, but individual 
private practices focused on a more limited set of methods, dictated by 
the training, technical capabilities and professional interest of the pro- 
vider. Most frequently, private providers mentioned only those methods 
available in their practice or clinic, but left it up to the client to choose 
what she considered the most appropriate method. Providers differentiate 
among the types of IUDs, oral pills and injectables, although most chose 
not to provide NET-EN because of its perceived drawbacks (e.g. difficulty 
of procuring appropriate needles, difficulty and painfulness of administra- 
tion]. 
Cyclofem would be introduced within a context of choice within the 
private sector, provided private practitioners like the method. It cannot 
be assumed that they will decide to stock the method, however. The cost 
of Cyclofem, its accessibility and the level of client demand are likely to 
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determine whether or not they do so. Certainly, the frequency of client 
visits and fewer side-effects would be attractive features for private prac- 
titioners. The importance of Cyclofem in expanding choice is primarily 
its ability to avoid the bleeding irregularities that frequently accompany 
DMPA. In the private sector this contribution is, however, of somewhat 
lesser importance as providers indicated that good counseling typically 
overcomes women’s discomfort with amenorrhea. 
Conclusions: Implications of Cyclofem Introduction for Choice 
in the Indonesian Program 
The relationship between choice and the introduction of new contracep- 
tive technology is complex. Many factors determine what range of options 
exist for those who wish to limit or space childbearing. The technology 
itself, with its specific intrinsic characteristics, is only one among several 
determinants. Choice is a function of the new method, the other existing 
methods, the needs of users, and of the managerial capability of the service 
delivery system to assure both technical and interpersonal quality of care. 
Findings presented in this paper reveal that although Cyclofem introduc- 
tion has broadened women’s choice to some extent in the introductory 
trial settings, conditions of routine service delivery reveal a range of 
weaknesses likely to negate the potential contribution of an additional 
injectable. 
Before discussing these implications further, the generalizability of 
study findings to the Indonesian Family Planning Program as a whole 
must be addressed. While the total number of study sites is relatively 
small, the sites include four of six Cyclofem trial centers, and taken as a 
whole, over-represent health centers and regions with strong management 
and service delivery capabilities. The fact that a variety of weaknesses in 
routine service delivery were observed in both the trial and non-trial 
health centers suggests that these weaknesses are present on a larger 
scale. Moreover, many of the identified constraints appear to be program 
constants rather than variables. For example, the push towards long- 
acting methods, the de-emphasis of injectables generally within the public 
sector, the inability to distinguish between NET-EN and DMPA in the 
record keeping system, and the inattention to information-giving and 
counseling are all program constants well known to the family planning 
community in Indonesia. Furthermore, observations were corroborated 
by interviews with high level Ministry of Health and BKKBN officials, 
and documented in other reports.6,7,10,12J3,15 
Thus, we feel confident in our conclusion that if the introduction of 
a once-a-month injectable is to expand women’s options in Indonesia, 
considerable adaptations in operational policy and program management 
would be necessary. Changes would be required in counseling and infor- 
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mation-giving, in the technical dimensions of care (as discussed by Lubis 
et al.” in this volume), the training of staff, supervision, record keeping 
systems, the provision of appropriate logistics and supplies, and in policy 
support for expanded options rather than a more narrow emphasis on 
long-acting methods. Given the scale and complexity of the Indonesian 
National Family Planning Program, such adaptations amount to both a 
significant organizational burden and to a change in direction which policy 
makers may be unwilling to pursue. 
The introductory trial of Cyclofem in Indonesia occurs at a time when 
the family planning program is coping with the managerial implications 
of the introduction and scaled-up service delivery of Norplant. As Ward 
and colleagues indicated, I5 Norplant introduction suffered from weak- 
nesses in regard to informed choice, access to removal on demand and 
technical quality of care. The service delivery system was not capable of 
adjusting to the requirements of this new technology at the pace with 
which introduction proceeded, thereby jeopardizing not only the principle 
of informed choice, but other dimensions of the quality of care. Introduc- 
tion of Cyclofem in Indonesia at this point in time would put added stress 
on an already overburdened health care system. 
Maintaining or improving quality of care in the delivery of existing 
contraceptive methods is an additionally important consideration for the 
introduction of new methods. The introductory study of Cyclofem in 
Indonesia coincides with an increasing recognition among senior policy 
makers and program managers of the weaknesses in the quality of service 
delivery of existing program methods, especially in regard to long-acting 
methods. In some program settings, such improvements in quality of care 
might provide economies of scale for the introduction of new methods, 
as the necessary administrative and service delivery adjustments or even 
the training could incorporate the requirements for the new method as 
well. Given the limits in organizational capacity and resources, however, 
incremental approaches focused on improvements in the existing method 
mix may be preferred, particularly if the properties of the new technology 
do not greatly expand the range of options available to women. 
The costs of adapting service delivery systems to the requirements of 
new technology may be extensive, especially in countries with the scale 
and complexity of the Indonesian program. The introductory study of 
Cyclofem in Indonesia takes place at a time when the program must 
move towards financial self-sufficiency. Given this and other priorities, 
the resources for the necessary managerial and health service adaptation 
may not be available to assure quality of care and choice in the introduc- 
tion of Cyclofem. Selective introduction of Cyclofem into urban areas, 
or certain regions, might be appropriate from the perspective of both costs 
and demand for the method. Selective introduction of new methods within 
public sector programs, however, is often not a politically acceptable 
522 Contraception 1994:49, May 
Role of Cyclofem in Indonesia: Simmons et al. 
alternative. Policy makers are hesitant to pursue this route, implying that 
Cyclofem should either be introduced on a national scale or not at all. 
Selective introduction into the private sector, or within the social 
marketing program, on the other hand, is another alternative to be 
considered. Findings from this study indicate that categorical assump- 
tions about high quality of care in the private sector are unwarranted. 
The private sector in Indonesia exhibits diverse quality of care character- 
istics. Some of the institutions are equipped to handle the service 
delivery adaptations to once-a-month injectables without major diffi- 
culty, provided they receive support with training and instructional 
materials. Other segments of the private sector-especially private 
providers in rural areas-are much less likely to provide such new 
technology with appropriate levels of quality of care, without significant 
program inputs from the public sector. 
Health service delivery systems of other family planning programs in 
many other countries of the non-industrialized world are similar to the 
service delivery system in Indonesia. In fact, the Indonesian program 
compares favorably in terms of its administrative capabilities to many 
other developing country programs. In such settings, the addition of new 
technology must be considered with much caution. When programs do 
not manage to provide existing contraceptives with appropriate standards 
of care, the addition of new technology does not expand choice. These 
points are particularly important for those settings in which injectables 
already exist. In fact, health service delivery research in Bangladesh has 
concluded that quality of care would be improved if the Bangladesh na- 
tional program would withdraw NET-EN from the program, leaving only 
one injectable within the system. I6 This recommendation argues that 
such removal would, in fact, improve quality of service delivery. 
If new contraceptive technology is to expand choice, careful assess- 
ments of the existing method mix, of the service delivery context must 
be undertaken. In countries with relatively stronger service delivery sys- 
tems, or with the resources to adapt to the requirements of once-a-month 
injectables, the conditions for effective broadening of choice might exist. 
The potential for increased choice would be particularly great in settings 
where injectables are not currently available, or where, as in several coun- 
tries in Latin America, Cyclofem could replace a widely used high-dose 
once-a-month injectable. The improved characteristics of a low-dose once- 
a-month injectable certainly increases women’s options. Additionally, a 
once-a-month injectable such as Cyclofem holds promise for very young 
women desiring rapid return to ovulation. In fact, Indonesia might well 
be a case in which Cyclofem could find a niche among this population. 
However, without the requisite conditions in service delivery manage- 
ment, the addition of a once-a-month injectable does not enhance choice, 
but threatens to diminish it. 
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